Skip to main content

Vogt-Koyanagi-Harada syndrome (review of case reports)


Vogt–Koyanagi–Harada (VKH) disease, also known as uveomeningitic syndrome, is a multisystem autoimmune disorder directed against any melanocyte-containing organ, including the eye, central nervous system, auditory, and integumentary system. We present a case of an African woman with total deafness and blindness of VKH, and discuss the histological characteristics, and review the classification and the management of VKH. The most important factor for prognosis is the immediate treatment. The rarity of this syndrome makes its diagnosis a challenge and the presence of deafness, tinnitus, and vertigo must be considered in its diagnosis.


  1. Koyanagi Y. Dysakusis, Alopecia und Poliosis bei schwerer Uveitis nicht traumatischen Ursprugs. Klin Monatsbl Augenheilkd. 1929; 82: 194–211

    Google Scholar 

  2. Vogt A. Early graying of cilia and remarks about the genaten sudden Eintreitt of this change. Klin Monatsbl Augenheilkd. 1906; 44: 228–242

    Google Scholar 

  3. Harada E. Acute diffuse choroiditis. Acta Soc Ophthalmol Jpn. 1926; 30: 356–378

    Google Scholar 

  4. Ohno S, Minakawa R, Matsuda H. Clinical studies of Vogt-Koyanagi-Harada’s disease. Jpn J Ophthalmol. 1988; 32: 334–343

    CAS  PubMed  Google Scholar 

  5. Rao NA. Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye (Lond). 1997;11(Pt 2):213–216

    Article  Google Scholar 

  6. Read RW, Rechodouni A, Butani N, Johnston R, LaBree LD, Smith RE, Rao NA. Complications and prognostic factors in Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2001; 131: 599–606

    CAS  Article  Google Scholar 

  7. Rao N, Blackman H, Franklin R, Meislar D, Sheppard J, Chalmers B, et al. VKH Syndrome, Panuvitis, Basic and Clinical Science Course, Sec 9. San Francisco: American Academy of Ophthalmology; 1998. pp. 130–133.

    Google Scholar 

  8. Hiraki Y, Kuwasaki N, Shoji H, Kaji M, Kuboshiro T. VKH syndrome with multiple cranial nerve palsies. Rinsho Shinkeigaku. 1981; 29: 54–58

    Google Scholar 

  9. Najman-Vainer J, Levinson RD, Graves MC, Nguyen B-T, Engstrom RE Jr., Holland GN. An association between Vogt-Koyanagi-Harada disease and Guillain-Barré syndrome. Am J Ophthalmol. 2001;131:615–619

    CAS  Article  Google Scholar 

  10. Gruich MJ, Evans OB, Storey JM, Bradley ST, Chen CJ. Vogt-Koyanagi-Harada syndrome in a 4-year-old child. Pediatr Neurol. 1995; 13: 50–51

    CAS  Article  Google Scholar 

  11. Shindo Y, Inoko H, Yamamoto T, Ohno S. HLA-DRB1 typing of Vogt-Koyanagi-Harada’s disease by PCR-RFLP and the strong association with DRB1(*)0405 and DRB1(*)0410. Br J Ophthalmol. 1994; 78: 223–226

    CAS  Article  Google Scholar 

  12. Islam SMM, Numaga J, Fujino Y, Hirata R, Matsuki K, Maeda H, Masuda K. HLA class II genes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994; 35: 3890–3896

    CAS  PubMed  Google Scholar 

  13. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000; 165: 7323–7329

    CAS  Article  Google Scholar 

  14. Yamaki K, Gocho K, Sakuragi S. Pathogenesis of Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2002; 42: 13–23

    Article  Google Scholar 

  15. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001; 131: 647–652

    CAS  Article  Google Scholar 

  16. Rubsamen PE, Gass JDM. Vogt-Koyanagi-Harada syndrome: clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991; 109: 682–687

    CAS  Article  Google Scholar 

  17. Sasamoto Y, Ohno S, Matsuda H. Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease. Ophthalmologica. 1990; 201: 162–167

    CAS  Article  Google Scholar 

  18. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130: 492–513

    CAS  Article  Google Scholar 

  19. Rao NA. Management of intraocular inflammation. In: Ryan SJ, editor. Retina. Vol. 2 3rd ed. Philadelphia: Mosby; 2001.

    Google Scholar 

  20. Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm. 2006; 14: 87–90

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Arwa AlKhunaizi MD.

Additional information

Conflicts of interest

There are no conflicts of interest.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

AlBahkaly, S., AlKhunaizi, A. & Algamdi, Z. Vogt-Koyanagi-Harada syndrome (review of case reports). Egypt J Otolaryngol 28, 275–277 (2012).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • human leukocyte antigen
  • immunomodulatory therapy
  • Vogt-Koyanagi-Harada